Skip to main content

Advertisement

Log in

Response to: Biosimilars for vasculitis: promise requires validation by quality studies

  • Letter to the Editor
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Mittal S, Naidu GSRSNK, Jha S, Rathi M, Nada R, Minz RW, Sharma K, Dhir V, Jain S, Sharma A (2020) Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05261-7

  2. Misra DP, Patro P, Agarwal V (2020) Biosimilars for vasculitis: promise requires validation by quality studies. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05309-8

  3. Lee S, Lee H, Kim E (2019) Comparative efficacy and safety of biosimilar rituximab and originator rituximab in rheumatoid arthritis and non-Hodgkin’s lymphoma: a systematic review and meta-analysis. BioDrugs Clin Immunother Biopharm Gene Ther 33(5):469–483

    Google Scholar 

  4. Misra D, Naidu GK, Sharma A (2019) Recent advances in the management of antineutrophil cytoplasmic antibody-associated vasculitis. Indian J Rheumatol 14(3):218–228

    Article  Google Scholar 

  5. Shobha V, Rao V, Desai A, Jois R, Srikantiah C, Dharmanand B, Kumar S, Kumar P, Dharmapalaiah C, Mahendranath KM, Prasad S, Daware M, Singh Y, Karjigi U (2019) Prescribing patterns and safety of biologics in immune-mediated rheumatic diseases: Karnataka biologics cohort study group experience. Indian J Rheumatol 14(1):17–20

    Article  Google Scholar 

  6. Heath R, Iacovou A, Ashley C, Antonelou M, Salama A (2019) FP208clinical evaluation of biosimilar anti-CD20 monoclonal antibody with rituximab in the treatment of ANCA-associated vasculitis. Nephrol Dial Transplant [Internet]. [cited 2020 Aug 9];34(gfz106.FP208). Available from: https://doi.org/10.1093/ndt/gfz106.FP208

  7. Incidence of adverse events in patients treated with intended copies of biologic therapeutic agents in Colombia and Mexico [Internet]. ACR Meeting Abstracts. [cited 2019 Jul 22]. Available from: https://acrabstracts.org/abstract/incidence-of-adverse-events-in-patients-treated-with-intended-copies-of-biologic-therapeutic-agents-in-colombia-and-mexico/

  8. Sharma A, Naidu GSRSNK, Rathi M, Verma R, Modi M, Pinto B, Sharma K, Dhir V, Singhal M, Prakash M, Nada R, Panda NK, Minz RW (2018) Clinical features and long-term outcomes of 105 granulomatosis with polyangiitis patients: a single center experience from North India. Int J Rheum Dis 21(1):278–284

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aman Sharma.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

See related article https://doi.org/10.1007/s10067-020-05309-8

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mittal, S., Naidu, G.S.R.S.N.K. & Sharma, A. Response to: Biosimilars for vasculitis: promise requires validation by quality studies. Clin Rheumatol 39, 3155–3156 (2020). https://doi.org/10.1007/s10067-020-05381-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05381-0

Navigation